<p>Immunome（纳斯达克：IMNM - 获取免费报告）于周四公布了季度财报。该公司报告的每股收益为（$0.65），低于分析师一致预期的（$0.57），差距为（$0.08），据 Zacks 报道。Immunome 的股本回报率为负 77.37%，净利润率为负 1,687.08%。</p>
<h2>Immunome 价格表现</h2>
<ul>
<li>3 只小盘股具有巨大的增长潜力</li>
</ul>
<p>IMNM 股票在周五下跌了$0.26，报$15.24。该公司的股票交易量为 1,665,412 股，而其平均交易量为 1,235,020 股。该股票的市值为 13.3 亿美元，市盈率为-5.17，贝塔值为 1.96。Immunome 的 52 周低点为$5.15，52 周高点为$17.87。该公司的 50 日移动平均价格为$12.83，200 日移动平均价格为$10.50。</p>
<h2>华尔街分析师观点</h2>
<p>IMNM 已成为多份研究报告的主题。Wedbush 在周五重申了 “跑赢大盘” 的评级，并将 Immunome 的目标价设定为$21.00。高盛集团在 9 月 22 日的研究报告中开始覆盖 Immunome 的股票。他们给予该公司 “买入” 评级，目标价为$26.00。Guggenheim 在 8 月 25 日的研究报告中重申了 “买入” 评级，并将 Immunome 的目标价设定为$25.00。Weiss Ratings 在 10 月 8 日的报告中重申了 Immunome 的 “卖出（d-）” 评级。最后，Wall Street Zen 在周六将 Immunome 的评级从 “持有” 下调至 “卖出”。十位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为$23.20。</p>
<p><strong>获取我们最新的 IMNM 股票分析</strong></p>
<h2>Immunome 的机构交易</h2>
<p>机构投资者和对冲基金最近对该股票的持仓进行了调整。法国巴黎银行金融市场在第二季度将其在 Immunome 的股份增加了 81.8%。法国巴黎银行金融市场现在拥有 6,464 股该公司的股票，价值$60,000，此前在上个季度增持了 2,909 股。Tower Research Capital LLC TRC 在第二季度将其在 Immunome 的持仓增加了 121.2%。Tower Research Capital LLC TRC 现在拥有 6,938 股该公司的股票，价值$65,000，此前在此期间购买了 3,802 股。Creative Planning 在第二季度购买了 Immunome 的新股份，价值约为$167,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Immunome 的持仓增加了 44.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 46,821 股该公司的股票，价值$316,000，此前在上个季度增持了 14,398 股。最后，Rhumbline Advisers 在第二季度将其在 Immunome 的持仓增加了 22.0%。Rhumbline Advisers 现在拥有 108,414 股该公司的股票，价值$1,008,000，此前在此期间增持了 19,526 股。机构投资者和对冲基金持有该公司 44.58% 的股份。</p>
<h2>Immunome 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immunome, Inc 是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在进行的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票超过 Immunome</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>Rivian 的图表显示可以购买，但一些分析师仍然表示不买</li>
<li>上海证券交易所综合指数是什么？</li>
<li>e.l.f.的抛售是购买的好时机，分析师表示</li>
<li>内部人士出售解释：这能否影响你的投资选择？</li>
<li>T-Mobile 是最被低估的大型股——现在是购买的时候吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Immunome 吗？</h2>
<p>在你考虑 Immunome 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immunome 并不在名单上。</p>
<p>虽然 Immunome 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

IMNM

<p>Immunome（纳斯达克代码：IMNM）报告本季度每股收益为（$0.65），低于预期的（$0.57），差距为（$0.08）。该公司的股本回报率为负 77.37%，净利润率为负 1,687.08%。股价下跌至$15.24，市值为 13.3 亿美元。分析师的评级意见不一，普遍评级为 “适度买入”，平均目标价为$23.20。机构投资者持有该股票的 44.58%，该公司专注于开发靶向癌症疗法</p>

<p>Immunome (NASDAQ:IMNM - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08), Zacks reports. Immunome had a negative return on equity of 77.37% and a negative net margin of 1,687.08%.</p>
<div class="lb-trans"><p>Immunome（纳斯达克：IMNM - 获取免费报告）于周四公布了季度财报。该公司报告的每股收益为（$0.65），低于分析师一致预期的（$0.57），差距为（$0.08），据 Zacks 报道。Immunome 的股本回报率为负 77.37%，净利润率为负 1,687.08%。</p>
</div><h2>Immunome Price Performance</h2>
<div class="lb-trans"><h2>Immunome 价格表现</h2>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盘股具有巨大的增长潜力</li>
</ul>
</div><p>Shares of IMNM stock traded down $0.26 on Friday, hitting $15.24. The company's stock had a trading volume of 1,665,412 shares, compared to its average volume of 1,235,020. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -5.17 and a beta of 1.96. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $17.87. The firm's fifty day moving average price is $12.83 and its 200-day moving average price is $10.50.</p>
<div class="lb-trans"><p>IMNM 股票在周五下跌了$0.26，报$15.24。该公司的股票交易量为 1,665,412 股，而其平均交易量为 1,235,020 股。该股票的市值为 13.3 亿美元，市盈率为-5.17，贝塔值为 1.96。Immunome 的 52 周低点为$5.15，52 周高点为$17.87。该公司的 50 日移动平均价格为$12.83，200 日移动平均价格为$10.50。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>IMNM has been the subject of several research reports. Wedbush restated an &#34;outperform&#34; rating and set a $21.00 price target on shares of Immunome in a report on Friday. The Goldman Sachs Group assumed coverage on shares of Immunome in a research report on Monday, September 22nd. They issued a &#34;buy&#34; rating and a $26.00 target price for the company. Guggenheim reissued a &#34;buy&#34; rating and set a $25.00 target price on shares of Immunome in a research note on Monday, August 25th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Immunome in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered Immunome from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $23.20.</p>
<div class="lb-trans"><p>IMNM 已成为多份研究报告的主题。Wedbush 在周五重申了 “跑赢大盘” 的评级，并将 Immunome 的目标价设定为$21.00。高盛集团在 9 月 22 日的研究报告中开始覆盖 Immunome 的股票。他们给予该公司 “买入” 评级，目标价为$26.00。Guggenheim 在 8 月 25 日的研究报告中重申了 “买入” 评级，并将 Immunome 的目标价设定为$25.00。Weiss Ratings 在 10 月 8 日的报告中重申了 Immunome 的 “卖出（d-）” 评级。最后，Wall Street Zen 在周六将 Immunome 的评级从 “持有” 下调至 “卖出”。十位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为$23.20。</p>
</div><p><strong>Get Our Latest Stock Analysis on IMNM</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 IMNM 股票分析</strong></p>
</div><h2>Institutional Trading of Immunome</h2>
<div class="lb-trans"><h2>Immunome 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its stake in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after acquiring an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after purchasing an additional 3,802 shares during the period. Creative Planning bought a new stake in Immunome during the second quarter worth approximately $167,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company's stock valued at $316,000 after purchasing an additional 14,398 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company's stock valued at $1,008,000 after purchasing an additional 19,526 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该股票的持仓进行了调整。法国巴黎银行金融市场在第二季度将其在 Immunome 的股份增加了 81.8%。法国巴黎银行金融市场现在拥有 6,464 股该公司的股票，价值$60,000，此前在上个季度增持了 2,909 股。Tower Research Capital LLC TRC 在第二季度将其在 Immunome 的持仓增加了 121.2%。Tower Research Capital LLC TRC 现在拥有 6,938 股该公司的股票，价值$65,000，此前在此期间购买了 3,802 股。Creative Planning 在第二季度购买了 Immunome 的新股份，价值约为$167,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Immunome 的持仓增加了 44.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 46,821 股该公司的股票，价值$316,000，此前在上个季度增持了 14,398 股。最后，Rhumbline Advisers 在第二季度将其在 Immunome 的持仓增加了 22.0%。Rhumbline Advisers 现在拥有 108,414 股该公司的股票，价值$1,008,000，此前在此期间增持了 19,526 股。机构投资者和对冲基金持有该公司 44.58% 的股份。</p>
</div><h2>Immunome Company Profile</h2>
<div class="lb-trans"><h2>Immunome 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc 是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在进行的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Rivian’s Chart Says Go, But Some Analysts Still Say No</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Immunome</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>Rivian 的图表显示可以购买，但一些分析师仍然表示不买</li>
<li>上海证券交易所综合指数是什么？</li>
<li>e.l.f.的抛售是购买的好时机，分析师表示</li>
<li>内部人士出售解释：这能否影响你的投资选择？</li>
<li>T-Mobile 是最被低估的大型股——现在是购买的时候吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1OTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMNM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Immunome 吗？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Immunome 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immunome 并不在名单上。</p>
</div><p>While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunome 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Immunome（NASDAQ 代码：IMNM）宣布财务业绩